Compare
Two to four companies, one screen
The same numbers the feed and each dossier publish, lined up so you can weigh candidates against each other. Every figure is a public-filing estimate, identical for every subscriber, and the shaded cell in a row is simply the highest number in it — not a recommendation.
Add one more to line them up.
| GLYCYX MOR, INC. OncologyGrant-only Remove | |
|---|---|
| Momentum0–100 | 31 |
| Runwayestimate, months | — |
| Stage | Grant-only |
| Last raiseForm D, self-reported | No Form D on file |
| Lead investigator | JOHNSON, LORIN K |
| What changed | NIH R44 · $1.2M · A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)10mo ago · New grant |
| Full dossier → |
Momentum and runway are estimates derived from public federal filings, published identically to every subscriber. This is informational only and is not investment advice. How the numbers work